Publications by authors named "R Castellino"
Article Synopsis
- Recurrent brain tumors are a major cause of cancer-related deaths in children, and the study focused on indoximod, which inhibits a metabolic checkpoint called IDO and may enhance anti-tumor immunity post-chemotherapy.
- A phase I trial was conducted with 81 pediatric patients, using indoximod in combination with temozolomide or radiation, to assess its safety and determine the appropriate dosage.
- Results showed a median overall survival of 13.3 months for recurrent cases, with patients who responded to treatment experiencing significantly longer survival, and the findings indicate potential for further trials to evaluate indoximod's effectiveness in treating pediatric brain tumors.
Purpose: Treatment of wingless (WNT)-activated medulloblastoma (WNT+MB) with surgery, irradiation (XRT), and chemotherapy results in excellent outcomes. We studied the efficacy of therapy de-intensification by omitting XRT entirely in children with WNT+MB.
Patients And Methods: Tumors were molecularly screened to confirm the diagnosis of WNT+MB.
Background: Pediatric gliomas comprise a diverse set of brain tumor entities that have substantial long-term ramifications for patient survival and quality of life. However, the study of these tumors is currently limited due to a lack of authentic models. Additionally, many aspects of pediatric brain tumor biology, such as tumor cell invasiveness, have been difficult to study with currently available tools.
View Article and Find Full Text PDFPurpose: Profiling of pediatric cancers through deep sequencing of large gene panels and whole exomes is rapidly being adopted in many clinical settings. However, the most impactful approach to genomic profiling of pediatric cancers remains to be defined.
Methods: We conducted a prospective precision medicine trial, using whole-exome sequencing of tumor and germline tissue and whole-transcriptome sequencing (RNA Seq) of tumor tissue to characterize the mutational landscape of 127 tumors from 126 unique patients across the spectrum of pediatric brain tumors, hematologic malignancies, and extracranial solid tumors.